Please wait while we open this resource.
K
Clinical reviews
CLOPIDOGREL OR DUAL ANTIPLATELET THERAPY IN HIGH-ISCHEMIC-RISK PATIENTS
Severance Hospital, Yonsei University
PDF202612 pages385 KB
The study is an open-label noninferiority trial conducted in South Korea, enrolling patients with high-risk clinical or lesion characteristics. Participants were randomly assigned to receive either clopidogrel monotherapy or extended dual antiplatelet therapy (DAPT) for 24 months. The primary endpoint was net adverse clinical events, including death, myocardial infarction, stent thrombosis, stroke, or significant bleeding. The findings aim to clarify the optimal antiplatelet strategy for this patient population.
Sign in to open
Ask this resource
Answers use this document only.
Your first question is free.
More like this
Resources from the same specialty and type. Curated links will replace these when added.
Clinical Resources
Documents that extend or complement this resource.
SURVIVAL AFTER INITIAL STRESS TESTING VS ANATOMIC TESTING IN SUSPECTED CORONARY ARTERY DISEASE
Same clinical topic · Cardiology
PRACTICAL CARDIO-ONCOLOGY
Same clinical topic · Cardiology
OXFORD CARDIOLOGY LIBRARY: Hypertension
Same clinical topic · Cardiology
CARDIAC INVOLVEMENT IN PARASITIC INFECTIONS
Same clinical topic · Cardiology
The Athlete’s ECG
Same clinical topic · Cardiology
Antigen carbohydrate 125 as a biomarker in heart failure: a narrative review
Same clinical topic · Cardiology
Current ECG Aspects of Interatrial Block
Same clinical topic · Cardiology
Arrhythmic mitral valve prolapse in 2023: Evidence-based update
Same clinical topic · Cardiology
INTERPRETING THE NORMAL PACEMAKER
Same clinical topic · Cardiology